Provided by Tiger Trade Technology Pte. Ltd.

First Trust Nasdaq Pharmaceuticals ETF

41.27
+0.82002.03%
Post-market: 41.270.00000.00%18:39 EDT
Volume:1.26M
Turnover:52.12M
Market Cap:1.06B
PE:- -
High:41.37
Open:40.60
Low:40.60
Close:40.45
52wk High:43.52
52wk Low:28.77
Shares:25.80M
Float Shares:25.80M
Volume Ratio:15.04
T/O Rate:4.90%
Dividend:0.29
Dividend Rate:0.71%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial

Dow Jones
·
Oct 01

Eli Lilly’s Foundayo shows cardiovascular safety in type 2 diabetes study

TIPRANKS
·
Oct 01

Lilly's Oral Glp-1, Foundayo (Orforglipron), Demonstrated Cardiovascular Safety Alongside Sustained A1c Reduction and Weight Loss in Its Largest and Longest Type 2 Diabetes Study

THOMSON REUTERS
·
Oct 01

Eli Lilly - Achieve-4: Foundayo Shows 16% Lower Mace-4 and 23% Lower Mace-3 Risk vs Insulin Glargine

THOMSON REUTERS
·
Oct 01

Eli Lilly - Foundayo Shows Smaller Egrf Reduction and Greater Albuminuria Reduction vs Insulin Glargine

THOMSON REUTERS
·
Oct 01

U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s Camzyos® (Mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (Ohcm) in Adults and Pediatric Patients*

THOMSON REUTERS
·
Oct 01

Estee Lauder Cos. Cl a Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Abbott Laboratories Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Merck, 3M Share Losses Contribute to Dow's 286-Point Drop

Dow Jones
·
Oct 01

Bristol-Myers Squibb's Camzyos to Treat Heart Condition Receives FDA Approval for Pediatric Patients

MT Newswires Live
·
Oct 01

FDA: Approved Camzyos (Mavacamten) Capsules as First Treatment for Children with Symptomatic Obstructive Hypertrophic Cardiomyopathy - Website

THOMSON REUTERS
·
Oct 01

FDA Approves First Drug to Improve Functional Capacity and Symptoms in Children with Rare Inherited Heart Condition

THOMSON REUTERS
·
Oct 01

FDA: Camzyos Carries Boxed Warning for Heart Failure Risk, Restricted to Rems Program

THOMSON REUTERS
·
Oct 01

FDA approves Bristol Myers’ Camzyos capsules for children with oHCM

TIPRANKS
·
Oct 01

Dow Drops 150 Points on Losses for Shares of Sherwin-Williams Co., Merck

Dow Jones
·
Oct 01

Sector Update: Healthcare

MT Newswires Live
·
Oct 01

Bristol-Myers' Protocol Changes Add Risk, Keep Admilparant on Track, UBS Says

MT Newswires Live
·
Oct 01

BMY Expands Real-World Cancer Data With New AUGTYRO Study in Korea

TIPRANKS
·
Oct 01

Lilly’s Clazakizumab Trial Pushes Cardiovascular Inflammation Strategy Forward

TIPRANKS
·
Oct 01

AbbVie Wraps Key Early Trial on ABBV-722 Drug Interaction, Supporting Pipeline Confidence

TIPRANKS
·
Oct 01